A body shape index and sarcopenia risk in middle-aged and older adults: evidence from the China Health and Retirement Longitudinal Study Authors: Haibin Shang, Zhen Deng, Youzhi Lian, Youli Ai, Guozhong Li Published: 2025 ABSTRACT BackgroundThe A body shape index (ABSI) has been associated with various diseases, and existing research suggests a link with sarcopenia. However, systematic evaluations focusing on Asian populations—particularly middle-aged and older adults in China—remain insufficient, and the specific association mechanisms and predictive value have yet to be fully elucidated. This study aimed to examine this relationship utilizing data from the China Health and Retirement Longitudinal Study (CHARLS) database.MethodsA total of 1873 participants aged ≥ 45 years with complete data from the 2015 CHARLS were included. Eligibility criteria required the availability of: (1) parameters necessary for ABSI calculation, namely, waist circumference (WC), height, and weight; (2) sarcopenia assessment components (muscle mass, grip strength (GS), and physical performance); and (3) all relevant covariates. Sarcopenia was diagnosed according to AWGS2019 guidelines, defined as low muscle mass (appendicular skeletal muscle mass (ASM)/height2 < 7.0 kg/m2 for male, < 5.7 kg/m2 for female) in combination with either low GS (< 28 kg for male, < 18 kg for female) or impaired physical performance (gait speed < 1 m/s or chair stand time > 12 s). Three progressively adjusted weighted logistic regression models were constructed: Model 1 (unadjusted), Model 2 (adjusted for demographic variables, including age, sex, and marital status), and Model 3 (fully adjusted for demographic, lifestyle, and clinical variables, such as physical activity, chronic diseases, and depression). Predictive performance was assessed using receiver operating characteristic (ROC) curve analysis, and a K-nearest neighbors (KNN) algorithm was applied to determine variable importance.ResultsThe cross-sectional analysis demonstrated significant differences in ABSI between individuals with sarcopenia (n = 329) and those without (n = 1544), with mean ABSI values of 4.59 and 3.71, respectively. The prevalence of sarcopenia was approximately 17.57% in the study population. All three models consistently indicated a significant association between ABSI and sarcopenia: Model 1 (odds ratio = 5.85, 95% confidence interval: 4.73–7.33), Model 2 (odds ratio = 5.34, 95% confidence interval: 4.23–6.83), and Model 3 (odds ratio = 5.22, 95% confidence interval: 4.10–6.74). The ROC analysis revealed that the fully adjusted model yielded an area under the curve of 0.871, compared to 0.760 for the ABSI-only model. In the KNN model, ABSI ranked highest in feature importance.ConclusionsABSI is strongly associated with sarcopenia prevalence and functions as an independent indicator, suggesting its potential applicability in sarcopenia screening strategies.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40001-025-03513-3. Introduction Rosenberg initially introduced the concept of sarcopenia [1], a severe geriatric syndrome characterized by aging-related reductions in skeletal muscle mass, strength, and functional capacity [2]. This condition results in diminished physical performance and mobility, elevates the likelihood of falls, fractures, and disability, and is linked to hospitalization, loss of independence, and increased mortality. Furthermore, it imposes a substantial economic burden on patients and national healthcare systems [3, 4]. According to the 2019 Asian Working Group for Sarcopenia report, the prevalence of sarcopenia ranges from 5.5% to 25.7%, with rates of 5.1–21.0% among males and 4.1–16.3% among females [5]. Evidence indicates that factors such as physical inactivity, inadequate nutrition, tobacco use, extreme sleep duration, and diabetes are associated with an elevated risk of sarcopenia [6]. Given its high prevalence and the multifactorial nature of its risk factors, identifying additional risk factors is of considerable importance for the prevention and management of this condition. A body shape index (ABSI) is an anthropometric parameter standardized by waist circumference (WC) relative to height and body mass index (BMI), capable of predicting the risk of morbidity and mortality [7–9], with predictive performance markedly superior to that of WC and BMI. As a waist-girth-based anthropometric measure, ABSI is particularly suitable for identifying sarcopenic obesity. It has been demonstrated that ABSI assists in determining the risk of sarcopenia among overweight or obese individuals [10]. Furthermore, ABSI independently predicts the fat-free mass index (FFMI) in females and serves as a significant predictor of sarcopenia [11]. Given that the association between ABSI and sarcopenia risk remains inconclusive, ABSI measurement needs to be both simple and practicable. Establishing a definitive relationship between ABSI and sarcopenia would enhance predictive capacity and offer valuable reference for clinical research and therapeutic strategies in patients with sarcopenia. Despite mounting evidence linking body composition indices to sarcopenia, the predictive utility of ABSI remains underexplored in Asian populations. Regarding population specificity, the combined effect of ABSI and sarcopenia on mortality requires validation in Asian cohorts [12]. Furthermore, the clinical implications of bioelectrical impedance analysis (BIA) are unclear, and existing studies often fail to account for confounding factors, such as urban–rural disparities and occupational activity levels [13]. This study aims to investigate the association between ABSI and sarcopenia risk, compare its predictive performance with conventional anthropometric measures, and identify clinically actionable thresholds. By addressing these objectives, we seek to advance early sarcopenia screening paradigms in resource-limited settings. Materials and methods Data extraction Data from the 2015 China Health and Retirement Longitudinal Study (CHARLS) were utilized to investigate the association between ABSI and sarcopenia risk among Chinese adults aged 45 years and older. CHARLS is a nationally representative, large-scale survey of middle-aged and older adults in China, collecting questionnaire-based information from individuals and households (http://charls.pku.edu.cn/). Participants were recruited through a standardized multistage probability sampling procedure. First, 150 county-level units were randomly selected from 28 provinces, followed by the random selection of villages or urban communities within these units. Subsequently, eligible households were systematically sampled, and all age-qualified members (≥ 45 years) were invited to participate. Written informed consent (two copies per participant) was obtained by trained interviewers during home visits before conducting face-to-face interviews and physical assessments. Ethical approval for CHARLS was granted by the Institutional Review Board at Peking University, and all procedures complied with the Declaration of Helsinki. Initially, 21,805 participants from the 2015 wave were included. Participants were excluded if they met any of the following criteria: (1) age < 45 years or with missing age data; (2) incomplete data on ABSI calculation parameters (WC, height, or weight) and incomplete sarcopenia assessment data (missing muscle mass, grip strength (GS), or physical performance measurements); and (3) missing data on key covariates or missing outcome data (undetermined sarcopenia status). After applying these exclusion criteria, 1873 participants remained for analysis. Detailed exclusion criteria are presented in Fig. 1.Fig. 1Flowchart of the sample selection from CHARLS 2015 Flowchart of the sample selection from CHARLS 2015 Definition of outcome and exposure factor This study followed the AWGS2019 guidelines and implemented a standardized protocol for the assessment of sarcopenia. Physical function was evaluated by measuring gait speed using a standard 5-m measuring tape and an electronic stopwatch, as well as by conducting chair stand tests with armless chairs and an electronic stopwatch. Muscle strength was assessed with a Yuejian TMWL-1000 GS meter [14]. ASM was determined using a bioelectrical impedance analyzer (InBody 720), and both ASM and appendicular skeletal muscle mass index were calculated according to established formulas [15]. Quality control procedures included daily equipment calibration, operator training, environmental monitoring, and dual data entry verification to ensure diagnostic reliability and comparability. In this context, sarcopenia was defined as reduced muscle strength or impaired physical function. Specifically, the squared ratio of ASM to height (ASM/height2, kg/m2) was employed to quantify muscle mass [5]. Sex was coded as 1 for males and 2 for females; age was recorded in years, height in centimeters, and weight in kilograms. A deficit in muscle mass was diagnosed when ASM/height2 was less than 5.08 kg/m2 for females and less than 6.88 kg/m2 for males [16]. GS measurements were utilized to evaluate overall muscle strength, with thresholds for insufficient GS defined as less than 18 kg for females and less than 28 kg for males [5]. Physical function was further assessed using both the chair stand test and the walking speed test. Low physical function was defined as a gait speed of less than 1 m/s or completion of five chair stand repetitions in more than 12 s [5]. Therefore, participants presenting with both low muscle mass and reduced muscle strength, or with both low muscle mass and impaired physical function, were classified as having sarcopenia; all remaining individuals were categorized as non-sarcopenic. The ABSI was introduced as a novel anthropometric index of body mass, adjusted for WC while incorporating both height and weight, to more accurately reflect the degree of central abdominal obesity [10, 17]. Its specific formula is presented as follows [18]:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ABSI{\kern 1pt} = {\kern 1pt} \frac{WC}{{BMI^{{{2 \mathord{\left/ {\vphantom {2 3}} \right. \kern-0pt} 3}}} \times height^{{{1 \mathord{\left/ {\vphantom {1 2}} \right. \kern-0pt} 2}}} }}$$\end{document}ABSI=WCBMI2233×height1122where WC and height were measured in centimeters, and weight in kilograms was divided by height in meters squared to calculate BMI. In the cross-sectional statistical analysis, ABSI values were categorized into four groups according to quartile calculations: Q1 (≤ 3.47), Q2 (3.47–3.78), Q3 (3.78–4.18), and Q4 (> 4.18). By integrating WC, height, and weight, ABSI minimizes the collinearity inherent in traditional anthropometric indicators. Multi-model validation demonstrated that its independent predictive performance for sarcopenia exceeded that of BMI and WC, enabling the straightforward and accurate identification of populations at early risk. The linear association between ABSI and the logit was verified using the Box–Tidwell test, confirming the effect size that directly interprets unit change. Definition of covariates To evaluate the influence of potential confounding factors, several key covariates were included in this study, namely, sex, age [3, 19], history of falls, hip fractures [20], balance problems, smoking status [21], engagement in agricultural work [22], physical exercise [21], healthy lifestyle, depression [23], chronic disease [24], sleep duration [25], alcohol consumption [26], self-rated health [27], life satisfaction [28], marital status [29], and type of medical insurance [30] gait speed [31], chair standing test (sec, physical function) [32], GS, appendicular skeletal muscle mass, muscle mass, height, weight, BMI [33] and WC [34]. Detailed information on each covariate is presented in Table S1. Statistical analysis The stats package (v 4.2.2) (https://www.R-project.org/) was employed to analyze differences in exposure factors and covariates between sarcopenia and non-sarcopenia groups using the t test for continuous variables and the chi-square test for categorical variables (P < 0.05). The tableone package (v 0.13.2) [35] was used to generate the cross-sectional table. To further elucidate the relationship between ABSI and sarcopenia, weighted multivariate logistic regression analyses were conducted with the stats package (v 4.2.2). Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated, where the OR represented the ratio of the odds of the outcome occurring in the exposed group to that in the non-exposed group. These ORs were derived from a weighted multiple logistic regression model with three stepwise adjustments for confounding factors, all fitted using the R stats package. In model construction, ABSI was treated as a continuous variable and included in all three weighted multiple logistic regression models (Model 1, Model 2, and Model 3). Model 1 examined ABSI without adjustment for any covariates, enabling preliminary exploration of the degree of association between ABSI and sarcopenia in the absence of confounding factors. Model 2 was adjusted for age, marital status, and sex to evaluate whether the association changed after controlling for demographic confounders, thereby isolating their potential influence and producing results that more closely approximated the true relationship. Model 3 further incorporated fall history, hip fractures, balance problems, smoking status, engagement in agricultural work, physical exercise, healthy lifestyle, depression, chronic disease, sleep duration, alcohol consumption, self-rated health, life satisfaction, and medical insurance type into the adjustments made in Model 2. This comprehensive adjustment sought to minimize interference from all potential confounders, thereby presenting the most accurate and reliable association between ABSI and sarcopenia and providing robust evidence for the study’s conclusions. To assess the clinical value of the exposure factor identified in Model 1, receiver operating characteristic (ROC) curve analysis was performed with the R package pROC (v 1.18.0) [36] to evaluate the predictive ability of ABSI for sarcopenia. The critical value of ABSI for ROC analysis was 4.655184. Furthermore, to verify that ABSI functions as a stronger predictive factor than BMI or WC, ROC curves for BMI and WC in predicting sarcopenia were also generated. Finally, to confirm the stability of the association between ABSI and sarcopenia under the influence of different covariates, a stratified association analysis was performed based on Model 3. Subsequently, the ROC curve for Model 3 was generated using the pROC package (v 1.0.12) [37] to evaluate the capacity of ABSI to predict sarcopenia. In cases, where model underfitting occurred, regularized logistic regression was applied to optimize model performance, after which the ROC curve was plotted for performance assessment. The KNN model was then constructed using the software package (v 6.0–93) [38]. Covariate rankings obtained through cross-validation and variable permutation importance measures in the K-nearest neighbors (KNN) model were compared with the principal logistic regression findings to ensure consistency. In addition, the predictive value of ABSI relative to other covariates in stratified analyses for the occurrence of myasthenia gravis and sarcopenia was examined. Based on Model 3, and utilizing the rms package (v 6.5–0) [39], restricted cubic splines (RCS) curves were plotted with the 10th, 50th, and 90th percentiles as knots to investigate the association between ABSI and sarcopenia. The selection of these knots allowed for a comprehensive depiction of variable trends across the entire numerical range, particularly capturing variations at both extremes and the midpoint of the distribution. Critical inflection points for linearity were identified through segmented regression to fit a piecewise linear relationship between ABSI and sarcopenia. R software (v 4.2.2) was employed for all statistical analyses, and a p value < 0.05 was considered indicative of statistical significance. Results Association between ABSI and sarcopenia The cross-sectional analysis indicated that among the 1873 participants, 329 were classified as having sarcopenia and 1544 as non-sarcopenic. Significant differences (P < 0.05) between the sarcopenia and non-sarcopenia groups were observed in ABSI, age, fall history, physical exercise, depression, sleep duration, self-rated health, marital status, life satisfaction, type of medical insurance, gait speed, chair standing test (Sec, physical function), GS, appendicular skeletal muscle mass, muscle mass, height, weight, BMI and WC (Table 1). According to the quartile grouping, the corresponding BMI grouping in the Q4 group of ABSI data is as follows: in the highest ABSI quartile, most participants fell into the underweight (n = 131) or normal weight (n = 335) categories, with only 2 cases classified as overweight and 1 case as obese (Table 2). Subsequently, three weighted multivariate logistic regression models were applied to examine the association between ABSI and sarcopenia (Table 3). Model 1 (OR 5.85, 95%CI 4.73–7.33), Model 2 (OR 5.34, 95%CI 4.23–6.83), and Model 3 (OR 5.22, 95%CI 4.10–6.74) all demonstrated a statistically significant association between ABSI and sarcopenia (P < 0.001). The strength of the association remained consistent with the progressive inclusion of covariates from Model 1 to Model 3. Stratified correlation analysis further confirmed that the relationship between ABSI and sarcopenia was robust across varying covariate conditions (OR: 5.22, 95%CI 4.10–6.74, P < 0.001). These findings suggest that ABSI functions as an independent correlation factor for sarcopenia. Table 1Baseline characteristic analysis of the participantslevelSarcopeniaNon_sarcopeniapn3291544ABSI (%)Q1447(29.0)21(6.4) < 0.001Q2418(27.1)50(15.2)Q3377(24.4)91(27.7)Q4302(19.6)167(50.8)Gender (%)Male164 ( 49.8)847 ( 54.9)0.111Female165 ( 50.2)697 ( 45.1)Age (%) > 75 years130 ( 39.5)60 ( 3.9) < 0.00145–60 years13 ( 4.0)210 ( 13.6)61–75 years186 ( 56.5)1274 ( 82.5)Wrestling (%)Yes70 ( 21.3)251 ( 16.3)0.035No259 ( 78.7)1293 ( 83.7)Hip_Fractures (%)Yes9 ( 2.7)22 ( 1.4)0.146No320 ( 97.3)1522 ( 98.6)Banlance_problems (%)Yes35 ( 10.6)116 ( 7.5)0.075No294 ( 89.4)1428 ( 92.5)Smoke (%)Yes158 ( 48.0)710 ( 46.0)0.54No171 ( 52.0)834 ( 54.0)Agricultural_work (%)Yes168 ( 51.1)851 ( 55.1)0.201No161 ( 48.9)693 ( 44.9)Physical_exercise (%)Yes179 ( 54.4)1068 ( 69.2) < 0.001No150 ( 45.6)476 ( 30.8)Healthy_style (%)Unhealthy44 ( 13.4)187 ( 12.1)0.589Healthy285 ( 86.6)1357 ( 87.9)Depression (%)No231 ( 70.2)1211 ( 78.4)0.002Yes98 ( 29.8)333 ( 21.6)Chronic_disease (mean (SD))1.61 (1.44)1.54 (1.47)0.38Sleep_time (%) < 6 h117 ( 35.6)468 ( 30.3) < 0.0016–8 h164 ( 49.8)938 ( 60.8) > 8 h48 ( 14.6)138 ( 8.9)Drink (%) > = 1 time a month82 ( 24.9)442 ( 28.6)0.062 < 1 time a month19 ( 5.8)131 ( 8.5)None228 ( 69.3)971 ( 62.9)Self_rated_health (%)Very good11 ( 3.3)124 ( 8.0) < 0.001Good25 ( 7.6)168 ( 10.9)Fair100 ( 30.4)522 ( 33.8)Poor121 ( 36.8)551 ( 35.7)Very poor72 ( 21.9)179 ( 11.6)Life_satisfaction (%)Very good24 ( 7.3)99 ( 6.4)0.005Good132 ( 40.1)564 ( 36.5)Fair142 ( 43.2)795 ( 51.5)Poor20 ( 6.1)68 ( 4.4)Very poor11 ( 3.3)18 ( 1.2)Marital_status (%)Married233 ( 70.8)1314 ( 85.1) < 0.001Separated8 ( 2.4)45 ( 2.9)Other types88 ( 26.7)185 ( 12.0)Medical insurance type (%)Urban employee basic18 ( 5.5)261 ( 16.9) < 0.001Urban–rural resident basic7 ( 2.1)81 ( 5.2)New rural cooperation293 ( 89.1)1136 ( 73.6)Urban rural4 ( 1.2)18 ( 1.2)Government-funded3 ( 0.9)28 ( 1.8)Others4 ( 1.2)20 ( 1.3)GS (mean (SD))4.00 (1.53)3.18 (2.20) < 0.001Sec (mean (SD))12.60 (5.68)8.48 (1.83) < 0.001Physical_function (%)High Physical function166 ( 50.5)1544 (100.0) < 0.001Low Physical function163 ( 49.5)0 ( 0.0)Muscle_quality (mean (SD))5.57 (1.00)7.01 (1.13) < 0.001Muscle_quality_diagnosis (%)High muscle quality0 ( 0.0)1544 (100.0) < 0.001Low muscle quality329 (100.0)0 ( 0.0)Muscular_strength (mean (SD))19.24 (6.49)31.35 (14.57) < 0.001Muscular_strength_diagnosis (%)High muscular strength57 ( 17.3)1544 (100.0) < 0.001Low muscular strength272 ( 82.7)0 ( 0.0)ASM (mean (SD))13.27 (3.56)17.87 (3.94) < 0.001Height (mean (SD))153.08 (8.72)158.90 (8.88) < 0.001Weight (mean (SD))43.92 (5.40)61.88 (9.53) < 0.001BMI (%)Underweight136 ( 41.3)0 ( 0.0) < 0.001Normal weight192 ( 58.4)751 ( 48.6)Overweight1 ( 0.3)609 ( 39.4)Obese0 ( 0.0)184 ( 11.9)Waist_circumference (mean (SD))73.16 (10.82)87.23 (12.58) < 0.001ABSI A body shape index, SD standard deviation, GS grip strength, Sec Seconds, BMI body mass index.Table 2The ABSI quartile BMI classification tableABSIABSI_1BMISarcopenia4.638314Q4Normal weightNon_sarcopenia4.557812Q4Normal weightNon_sarcopenia4.254811Q4Normal weightNon_sarcopenia7.399006Q4UnderweightSarcopenia6.070689Q4UnderweightSarcopenia4.235808Q4Normal weightNon_sarcopenia4.522269Q4Normal weightNon_sarcopenia4.473606Q4Normal weightNon_sarcopenia4.257242Q4Normal weightNon_sarcopenia5.235611Q4UnderweightSarcopenia4.473394Q4Normal weightNon_sarcopenia6.285027Q4UnderweightSarcopenia4.242901Q4Normal weightNon_sarcopenia5.683479Q4UnderweightSarcopenia4.41169Q4Normal weightNon_sarcopenia4.285241Q4Normal weightNon_sarcopenia5.497933Q4UnderweightSarcopenia4.635501Q4Normal weightSarcopenia4.283908Q4Normal weightNon_sarcopenia4.178743Q4Normal weightNon_sarcopenia4.751603Q4Normal weightNon_sarcopenia5.102532Q4UnderweightSarcopenia4.186851Q4Normal weightNon_sarcopenia4.235321Q4Normal weightNon_sarcopenia4.291753Q4Normal weightNon_sarcopenia4.245307Q4Normal weightNon_sarcopenia5.70972Q4UnderweightSarcopenia4.561631Q4Normal weightNon_sarcopenia5.900749Q4UnderweightSarcopenia4.226834Q4Normal weightNon_sarcopenia4.273165Q4Normal weightNon_sarcopenia4.420706Q4Normal weightNon_sarcopenia4.395983Q4Normal weightNon_sarcopenia5.926585Q4UnderweightSarcopenia4.311979Q4Normal weightNon_sarcopenia4.398941Q4Normal weightNon_sarcopenia5.267373Q4UnderweightSarcopenia6.167406Q4UnderweightSarcopenia6.403124Q4UnderweightSarcopenia4.26876Q4Normal weightSarcopenia4.288537Q4Normal weightNon_sarcopenia4.183899Q4Normal weightNon_sarcopenia4.323051Q4Normal weightNon_sarcopenia4.283391Q4Normal weightNon_sarcopenia4.504335Q4Normal weightNon_sarcopenia5.41665Q4UnderweightSarcopenia4.36588Q4Normal weightNon_sarcopenia4.406229Q4Normal weightNon_sarcopenia4.333Q4Normal weightSarcopenia4.473427Q4Normal weightNon_sarcopenia4.322941Q4Normal weightNon_sarcopenia4.279298Q4Normal weightNon_sarcopenia4.203531Q4Normal weightNon_sarcopenia4.378591Q4Normal weightNon_sarcopenia4.331641Q4Normal weightNon_sarcopenia4.866748Q4Normal weightNon_sarcopenia4.183566Q4Normal weightNon_sarcopenia4.5755Q4Normal weightNon_sarcopenia5.604355Q4UnderweightSarcopenia5.501778Q4UnderweightSarcopenia4.256737Q4Normal weightSarcopenia6.377073Q4UnderweightSarcopenia4.671774Q4Normal weightNon_sarcopenia4.191127Q4Normal weightSarcopenia4.506913Q4Normal weightNon_sarcopenia5.597231Q4UnderweightSarcopenia4.632497Q4Normal weightNon_sarcopenia4.346884Q4Normal weightNon_sarcopenia4.501246Q4Normal weightNon_sarcopenia4.549176Q4Normal weightNon_sarcopenia4.270237Q4Normal weightNon_sarcopenia4.379806Q4Normal weightNon_sarcopenia4.230625Q4Normal weightNon_sarcopenia4.542035Q4Normal weightNon_sarcopenia4.865234Q4Normal weightNon_sarcopenia4.584286Q4Normal weightNon_sarcopenia4.31009Q4Normal weightNon_sarcopenia4.228733Q4Normal weightNon_sarcopenia4.441327Q4Normal weightNon_sarcopenia4.336703Q4Normal weightNon_sarcopenia5.210876Q4UnderweightSarcopenia4.363753Q4Normal weightNon_sarcopenia4.452845Q4Normal weightNon_sarcopenia4.269671Q4Normal weightNon_sarcopenia5.004518Q4UnderweightSarcopenia4.525832Q4Normal weightNon_sarcopenia4.249Q4Normal weightNon_sarcopenia4.259266Q4Normal weightNon_sarcopenia4.427249Q4Normal weightNon_sarcopenia4.458493Q4Normal weightNon_sarcopenia4.475261Q4Normal weightNon_sarcopenia4.187679Q4Normal weightNon_sarcopenia4.231281Q4Normal weightNon_sarcopenia4.442931Q4Normal weightNon_sarcopenia4.37404Q4Normal weightNon_sarcopenia4.832043Q4Normal weightNon_sarcopenia5.657667Q4UnderweightSarcopenia5.795157Q4UnderweightSarcopenia5.840777Q4UnderweightSarcopenia5.75006Q4UnderweightSarcopenia4.639992Q4Normal weightNon_sarcopenia4.402077Q4Normal weightNon_sarcopenia4.412616Q4Normal weightNon_sarcopenia4.388037Q4Normal weightNon_sarcopenia4.923529Q4Normal weightNon_sarcopenia4.692086Q4Normal weightNon_sarcopenia4.24984Q4Normal weightNon_sarcopenia4.321464Q4Normal weightNon_sarcopenia4.454625Q4Normal weightNon_sarcopenia4.576621Q4Normal weightNon_sarcopenia4.616497Q4Normal weightNon_sarcopenia4.181073Q4Normal weightSarcopenia4.317543Q4Normal weightNon_sarcopenia4.230258Q4Normal weightNon_sarcopenia4.600182Q4Normal weightNon_sarcopenia5.190872Q4UnderweightSarcopenia4.253308Q4Normal weightNon_sarcopenia4.314122Q4Normal weightNon_sarcopenia4.196185Q4Normal weightNon_sarcopenia4.306254Q4Normal weightSarcopenia4.264484Q4Normal weightNon_sarcopenia4.330375Q4Normal weightNon_sarcopenia5.69687Q4UnderweightSarcopenia5.337085Q4UnderweightSarcopenia5.721682Q4UnderweightSarcopenia5.031311Q4Normal weightSarcopenia5.204317Q4UnderweightSarcopenia4.417349Q4Normal weightSarcopenia4.570285Q4Normal weightNon_sarcopenia4.496023Q4Normal weightSarcopenia4.196566Q4Normal weightNon_sarcopenia4.347043Q4Normal weightSarcopenia4.362127Q4Normal weightNon_sarcopenia4.270731Q4Normal weightNon_sarcopenia4.466557Q4Normal weightNon_sarcopenia4.863706Q4Normal weightNon_sarcopenia4.306637Q4Normal weightNon_sarcopenia4.18502Q4Normal weightNon_sarcopenia5.236741Q4UnderweightSarcopenia4.290092Q4Normal weightNon_sarcopenia4.231233Q4Normal weightNon_sarcopenia4.308906Q4Normal weightNon_sarcopenia4.242948Q4Normal weightNon_sarcopenia5.347391Q4UnderweightSarcopenia5.971124Q4UnderweightSarcopenia4.401209Q4Normal weightNon_sarcopenia4.258405Q4Normal weightNon_sarcopenia4.357052Q4Normal weightNon_sarcopenia4.375807Q4Normal weightNon_sarcopenia4.439015Q4Normal weightNon_sarcopenia4.218529Q4Normal weightNon_sarcopenia6.519317Q4UnderweightSarcopenia4.390694Q4Normal weightNon_sarcopenia5.847671Q4UnderweightSarcopenia4.529747Q4Normal weightNon_sarcopenia5.296678Q4UnderweightSarcopenia4.465241Q4Normal weightNon_sarcopenia4.409757Q4Normal weightSarcopenia4.745616Q4Normal weightNon_sarcopenia5.742569Q4UnderweightSarcopenia5.656498Q4UnderweightSarcopenia6.615807Q4UnderweightSarcopenia4.181672Q4Normal weightSarcopenia4.342272Q4Normal weightNon_sarcopenia4.397362Q4Normal weightSarcopenia4.23041Q4Normal weightNon_sarcopenia4.573827Q4Normal weightSarcopenia5.895066Q4UnderweightSarcopenia4.379277Q4Normal weightNon_sarcopenia5.264956Q4UnderweightSarcopenia5.475501Q4UnderweightSarcopenia4.364495Q4Normal weightNon_sarcopenia5.648139Q4UnderweightSarcopenia4.220067Q4Normal weightNon_sarcopenia4.493273Q4Normal weightNon_sarcopenia4.241737Q4Normal weightNon_sarcopenia5.636824Q4UnderweightSarcopenia4.630871Q4Normal weightNon_sarcopenia4.372478Q4Normal weightNon_sarcopenia4.182347Q4Normal weightNon_sarcopenia4.446807Q4Normal weightNon_sarcopenia6.182828Q4UnderweightSarcopenia4.64694Q4Normal weightNon_sarcopenia4.223132Q4Normal weightNon_sarcopenia6.096047Q4UnderweightSarcopenia4.277409Q4Normal weightNon_sarcopenia4.323253Q4Normal weightNon_sarcopenia4.684817Q4Normal weightNon_sarcopenia4.223393Q4Normal weightNon_sarcopenia4.179695Q4Normal weightNon_sarcopenia4.1968Q4Normal weightNon_sarcopenia6.783911Q4UnderweightSarcopenia5.220653Q4Normal weightSarcopenia4.625796Q4Normal weightNon_sarcopenia4.194381Q4Normal weightNon_sarcopenia4.307821Q4Normal weightNon_sarcopenia4.29772Q4Normal weightNon_sarcopenia4.564107Q4Normal weightNon_sarcopenia4.232933Q4Normal weightNon_sarcopenia4.20318Q4Normal weightNon_sarcopenia4.788759Q4ObeseNon_sarcopenia4.389952Q4Normal weightSarcopenia5.199168Q4UnderweightSarcopenia5.970384Q4UnderweightSarcopenia6.107819Q4UnderweightSarcopenia4.272127Q4Normal weightNon_sarcopenia4.68764Q4Normal weightNon_sarcopenia4.412089Q4Normal weightNon_sarcopenia4.761971Q4Normal weightSarcopenia4.416439Q4Normal weightNon_sarcopenia4.39129Q4Normal weightNon_sarcopenia4.367658Q4Normal weightNon_sarcopenia4.368056Q4Normal weightNon_sarcopenia6.683729Q4UnderweightSarcopenia4.223324Q4Normal weightNon_sarcopenia4.667663Q4Normal weightNon_sarcopenia4.774734Q4Normal weightNon_sarcopenia4.285324Q4Normal weightNon_sarcopenia4.631325Q4Normal weightNon_sarcopenia4.300815Q4Normal weightNon_sarcopenia5.672634Q4UnderweightSarcopenia5.656476Q4UnderweightSarcopenia4.244497Q4Normal weightNon_sarcopenia4.370203Q4Normal weightNon_sarcopenia4.251233Q4Normal weightNon_sarcopenia4.293205Q4Normal weightNon_sarcopenia4.200136Q4Normal weightSarcopenia4.182046Q4Normal weightNon_sarcopenia4.598027Q4Normal weightNon_sarcopenia4.375631Q4Normal weightNon_sarcopenia4.721021Q4Normal weightNon_sarcopenia4.181445Q4Normal weightNon_sarcopenia5.137674Q4UnderweightSarcopenia4.231365Q4Normal weightNon_sarcopenia4.362938Q4Normal weightNon_sarcopenia4.227252Q4Normal weightNon_sarcopenia5.5068Q4UnderweightSarcopenia4.617238Q4Normal weightNon_sarcopenia4.335104Q4Normal weightNon_sarcopenia4.716545Q4Normal weightNon_sarcopenia4.638178Q4Normal weightNon_sarcopenia4.349356Q4Normal weightNon_sarcopenia4.218318Q4Normal weightNon_sarcopenia4.267266Q4Normal weightNon_sarcopenia4.43579Q4Normal weightNon_sarcopenia5.343155Q4UnderweightSarcopenia4.47179Q4Normal weightSarcopenia4.50083Q4Normal weightNon_sarcopenia4.520369Q4Normal weightNon_sarcopenia4.382544Q4Normal weightNon_sarcopenia6.34471Q4UnderweightSarcopenia5.57698Q4UnderweightSarcopenia4.42441Q4Normal weightNon_sarcopenia5.168883Q4UnderweightSarcopenia4.493642Q4Normal weightNon_sarcopenia4.265202Q4Normal weightNon_sarcopenia4.396829Q4Normal weightNon_sarcopenia5.664721Q4UnderweightSarcopenia4.386757Q4Normal weightNon_sarcopenia6.128004Q4UnderweightSarcopenia4.609099Q4Normal weightNon_sarcopenia5.799416Q4UnderweightSarcopenia4.486169Q4Normal weightNon_sarcopenia4.516208Q4Normal weightNon_sarcopenia4.19134Q4Normal weightNon_sarcopenia4.204672Q4Normal weightSarcopenia5.877831Q4UnderweightSarcopenia4.219256Q4OverweightNon_sarcopenia5.534735Q4UnderweightSarcopenia4.658791Q4UnderweightSarcopenia5.492878Q4UnderweightSarcopenia4.285929Q4Normal weightNon_sarcopenia4.442532Q4Normal weightNon_sarcopenia4.339239Q4Normal weightNon_sarcopenia4.31664Q4Normal weightNon_sarcopenia4.673863Q4Normal weightNon_sarcopenia4.511361Q4Normal weightNon_sarcopenia4.59878Q4Normal weightNon_sarcopenia5.160385Q4UnderweightSarcopenia5.579677Q4UnderweightSarcopenia4.362242Q4Normal weightNon_sarcopenia4.508065Q4Normal weightNon_sarcopenia4.32228Q4Normal weightNon_sarcopenia5.890576Q4UnderweightSarcopenia4.179491Q4Normal weightNon_sarcopenia4.355058Q4Normal weightNon_sarcopenia4.310964Q4Normal weightNon_sarcopenia4.651577Q4Normal weightNon_sarcopenia4.397487Q4Normal weightNon_sarcopenia5.155519Q4UnderweightSarcopenia4.322021Q4Normal weightNon_sarcopenia4.763293Q4Normal weightSarcopenia4.382149Q4Normal weightNon_sarcopenia5.044086Q4OverweightNon_sarcopenia4.300043Q4Normal weightNon_sarcopenia4.27567Q4Normal weightNon_sarcopenia6.25915Q4UnderweightSarcopenia5.073643Q4UnderweightSarcopenia5.691024Q4UnderweightSarcopenia5.020184Q4UnderweightSarcopenia4.273165Q4Normal weightNon_sarcopenia4.342999Q4Normal weightNon_sarcopenia5.564682Q4UnderweightSarcopenia4.385227Q4Normal weightNon_sarcopenia4.518477Q4Normal weightNon_sarcopenia4.473168Q4Normal weightNon_sarcopenia4.884754Q4UnderweightSarcopenia5.427893Q4UnderweightSarcopenia4.467976Q4Normal weightNon_sarcopenia4.399092Q4Normal weightNon_sarcopenia4.502715Q4Normal weightNon_sarcopenia4.187069Q4Normal weightNon_sarcopenia4.456971Q4Normal weightNon_sarcopenia6.122187Q4UnderweightSarcopenia4.4832Q4Normal weightNon_sarcopenia4.790199Q4Normal weightNon_sarcopenia4.412476Q4Normal weightNon_sarcopenia4.27918Q4Normal weightNon_sarcopenia4.251233Q4Normal weightNon_sarcopenia4.412527Q4Normal weightNon_sarcopenia4.257142Q4Normal weightNon_sarcopenia4.317899Q4Normal weightNon_sarcopenia5.399014Q4UnderweightSarcopenia5.474267Q4UnderweightSarcopenia5.775Q4UnderweightSarcopenia4.337621Q4Normal weightNon_sarcopenia5.796601Q4UnderweightSarcopenia4.262025Q4Normal weightNon_sarcopenia4.210745Q4Normal weightNon_sarcopenia4.282286Q4Normal weightNon_sarcopenia5.176338Q4UnderweightSarcopenia4.344186Q4Normal weightSarcopenia5.372218Q4UnderweightSarcopenia5.535139Q4UnderweightSarcopenia5.844057Q4UnderweightSarcopenia5.360554Q4UnderweightSarcopenia4.952087Q4UnderweightSarcopenia4.610761Q4Normal weightNon_sarcopenia4.386712Q4Normal weightNon_sarcopenia6.049793Q4UnderweightSarcopenia6.146361Q4UnderweightSarcopenia5.778149Q4UnderweightSarcopenia6.025322Q4UnderweightSarcopenia4.970073Q4UnderweightSarcopenia5.570829Q4UnderweightSarcopenia6.079366Q4UnderweightSarcopenia5.862805Q4UnderweightSarcopenia4.276609Q4Normal weightNon_sarcopenia5.264207Q4UnderweightSarcopenia4.383771Q4Normal weightNon_sarcopenia4.563679Q4Normal weightNon_sarcopenia4.295431Q4Normal weightNon_sarcopenia4.297942Q4Normal weightSarcopenia4.817691Q4Normal weightNon_sarcopenia4.406486Q4Normal weightNon_sarcopenia4.392399Q4Normal weightNon_sarcopenia4.281383Q4Normal weightNon_sarcopenia4.202326Q4Normal weightNon_sarcopenia4.278942Q4Normal weightNon_sarcopenia4.71564Q4Normal weightNon_sarcopenia5.386049Q4Normal weightSarcopenia4.221479Q4Normal weightSarcopenia4.241557Q4Normal weightSarcopenia6.09953Q4UnderweightSarcopenia4.377059Q4Normal weightNon_sarcopenia4.437996Q4Normal weightNon_sarcopenia4.176608Q4Normal weightNon_sarcopenia6.172606Q4UnderweightSarcopenia4.274582Q4Normal weightNon_sarcopenia4.697897Q4Normal weightSarcopenia4.29182Q4Normal weightNon_sarcopenia4.462581Q4Normal weightNon_sarcopenia4.670934Q4Normal weightSarcopenia4.636023Q4Normal weightNon_sarcopenia4.26068Q4Normal weightNon_sarcopenia5.439305Q4UnderweightSarcopenia5.867187Q4UnderweightSarcopenia4.284376Q4Normal weightNon_sarcopenia4.481761Q4Normal weightNon_sarcopenia4.412045Q4Normal weightNon_sarcopenia4.311189Q4Normal weightNon_sarcopenia4.325872Q4Normal weightNon_sarcopenia4.536656Q4Normal weightNon_sarcopenia4.376419Q4Normal weightNon_sarcopenia4.189658Q4Normal weightNon_sarcopenia4.608637Q4Normal weightNon_sarcopenia6.437455Q4UnderweightSarcopenia4.342038Q4Normal weightNon_sarcopenia4.370609Q4Normal weightNon_sarcopenia4.205236Q4Normal weightNon_sarcopenia5.980591Q4UnderweightSarcopenia4.319214Q4Normal weightNon_sarcopenia4.311013Q4Normal weightSarcopenia5.64994Q4UnderweightSarcopenia4.987994Q4Normal weightNon_sarcopenia4.193891Q4Normal weightNon_sarcopenia4.515637Q4Normal weightNon_sarcopenia4.25067Q4Normal weightNon_sarcopenia4.347062Q4Normal weightNon_sarcopenia4.383824Q4Normal weightNon_sarcopenia4.202039Q4Normal weightNon_sarcopenia6.008328Q4UnderweightSarcopenia4.821759Q4Normal weightNon_sarcopenia6.305926Q4UnderweightSarcopenia4.387455Q4Normal weightNon_sarcopenia4.243806Q4Normal weightNon_sarcopenia4.242409Q4Normal weightNon_sarcopenia4.327901Q4Normal weightNon_sarcopenia4.255865Q4Normal weightNon_sarcopenia4.240103Q4Normal weightNon_sarcopenia5.35718Q4UnderweightSarcopenia5.394027Q4UnderweightSarcopenia4.40895Q4Normal weightSarcopenia4.232658Q4Normal weightNon_sarcopenia5.544959Q4UnderweightSarcopenia4.461295Q4Normal weightNon_sarcopenia4.224207Q4Normal weightNon_sarcopenia5.510093Q4UnderweightSarcopenia4.27705Q4Normal weightNon_sarcopenia4.785404Q4Normal weightNon_sarcopenia4.181365Q4Normal weightNon_sarcopenia5.583053Q4UnderweightSarcopenia5.28762Q4UnderweightSarcopenia6.975176Q4UnderweightSarcopenia4.273495Q4Normal weightNon_sarcopenia6.05842Q4UnderweightSarcopenia5.915357Q4UnderweightSarcopenia6.160379Q4UnderweightSarcopenia4.374814Q4Normal weightNon_sarcopenia4.403976Q4Normal weightNon_sarcopenia5.648034Q4UnderweightSarcopenia5.821023Q4UnderweightSarcopenia5.573704Q4UnderweightSarcopenia5.778015Q4UnderweightSarcopenia6.088959Q4UnderweightSarcopenia4.24565Q4Normal weightNon_sarcopenia4.209206Q4Normal weightNon_sarcopenia5.797126Q4UnderweightSarcopenia4.80996Q4Normal weightSarcopenia4.324875Q4Normal weightNon_sarcopenia4.260773Q4Normal weightNon_sarcopenia4.212502Q4Normal weightNon_sarcopenia6.064306Q4UnderweightSarcopenia4.229888Q4Normal weightNon_sarcopenia6.166475Q4UnderweightSarcopenia4.27919Q4Normal weightNon_sarcopenia4.211965Q4Normal weightNon_sarcopenia6.58795Q4UnderweightSarcopenia4.200208Q4Normal weightNon_sarcopenia4.495923Q4Normal weightNon_sarcopenia4.29405Q4Normal weightNon_sarcopenia4.325623Q4Normal weightNon_sarcopenia5.573089Q4UnderweightSarcopenia4.323512Q4Normal weightSarcopenia5.382588Q4UnderweightSarcopenia5.370839Q4UnderweightSarcopenia4.367726Q4Normal weightNon_sarcopenia6.641574Q4UnderweightSarcopenia4.623445Q4Normal weightSarcopenia4.282313Q4Normal weightSarcopenia5.916667Q4UnderweightSarcopenia4.256516Q4Normal weightNon_sarcopenia4.556854Q4Normal weightSarcopenia4.193878Q4Normal weightNon_sarcopenia4.23593Q4Normal weightNon_sarcopenia4.211456Q4Normal weightNon_sarcopenia5.556447Q4UnderweightSarcopenia5.823479Q4UnderweightSarcopenia4.348902Q4Normal weightNon_sarcopeniaTable 3Association between ABSI and risk of sarcopeniaSIIOR95% CIp_valueABSImodel 15.854.73–7.33 < 0.001ABSImodel 25.344.23–6.83 < 0.001ABSImodel 35.224.10–6.74 < 0.001Model 1 was included as the exposure factor ABSI and the outcome sarcopeniaModel 2 incorporates covariates such as gender, age and marital status on the basis of Model 1Model 3was further adjusted based on Model 2, including factors such as history of falls, history of hip fractures, any issues affecting balance, smoking, engagement in agricultural work for more than 10 years, physical exercise, healthy lifestyle score, depression, presence of chronic diseases, sleep duration, alcohol consumption, self-rated physical health, life satisfaction, and type of health insurance enrolled in ABSI A body shape index, OR odds ratios, CI confidence intervals Table 1Baseline characteristic analysis of the participantslevelSarcopeniaNon_sarcopeniapn3291544ABSI (%)Q1447(29.0)21(6.4) < 0.001Q2418(27.1)50(15.2)Q3377(24.4)91(27.7)Q4302(19.6)167(50.8)Gender (%)Male164 ( 49.8)847 ( 54.9)0.111Female165 ( 50.2)697 ( 45.1)Age (%) > 75 years130 ( 39.5)60 ( 3.9) < 0.00145–60 years13 ( 4.0)210 ( 13.6)61–75 years186 ( 56.5)1274 ( 82.5)Wrestling (%)Yes70 ( 21.3)251 ( 16.3)0.035No259 ( 78.7)1293 ( 83.7)Hip_Fractures (%)Yes9 ( 2.7)22 ( 1.4)0.146No320 ( 97.3)1522 ( 98.6)Banlance_problems (%)Yes35 ( 10.6)116 ( 7.5)0.075No294 ( 89.4)1428 ( 92.5)Smoke (%)Yes158 ( 48.0)710 ( 46.0)0.54No171 ( 52.0)834 ( 54.0)Agricultural_work (%)Yes168 ( 51.1)851 ( 55.1)0.201No161 ( 48.9)693 ( 44.9)Physical_exercise (%)Yes179 ( 54.4)1068 ( 69.2) < 0.001No150 ( 45.6)476 ( 30.8)Healthy_style (%)Unhealthy44 ( 13.4)187 ( 12.1)0.589Healthy285 ( 86.6)1357 ( 87.9)Depression (%)No231 ( 70.2)1211 ( 78.4)0.002Yes98 ( 29.8)333 ( 21.6)Chronic_disease (mean (SD))1.61 (1.44)1.54 (1.47)0.38Sleep_time (%) < 6 h117 ( 35.6)468 ( 30.3) < 0.0016–8 h164 ( 49.8)938 ( 60.8) > 8 h48 ( 14.6)138 ( 8.9)Drink (%) > = 1 time a month82 ( 24.9)442 ( 28.6)0.062 < 1 time a month19 ( 5.8)131 ( 8.5)None228 ( 69.3)971 ( 62.9)Self_rated_health (%)Very good11 ( 3.3)124 ( 8.0) < 0.001Good25 ( 7.6)168 ( 10.9)Fair100 ( 30.4)522 ( 33.8)Poor121 ( 36.8)551 ( 35.7)Very poor72 ( 21.9)179 ( 11.6)Life_satisfaction (%)Very good24 ( 7.3)99 ( 6.4)0.005Good132 ( 40.1)564 ( 36.5)Fair142 ( 43.2)795 ( 51.5)Poor20 ( 6.1)68 ( 4.4)Very poor11 ( 3.3)18 ( 1.2)Marital_status (%)Married233 ( 70.8)1314 ( 85.1) < 0.001Separated8 ( 2.4)45 ( 2.9)Other types88 ( 26.7)185 ( 12.0)Medical insurance type (%)Urban employee basic18 ( 5.5)261 ( 16.9) < 0.001Urban–rural resident basic7 ( 2.1)81 ( 5.2)New rural cooperation293 ( 89.1)1136 ( 73.6)Urban rural4 ( 1.2)18 ( 1.2)Government-funded3 ( 0.9)28 ( 1.8)Others4 ( 1.2)20 ( 1.3)GS (mean (SD))4.00 (1.53)3.18 (2.20) < 0.001Sec (mean (SD))12.60 (5.68)8.48 (1.83) < 0.001Physical_function (%)High Physical function166 ( 50.5)1544 (100.0) < 0.001Low Physical function163 ( 49.5)0 ( 0.0)Muscle_quality (mean (SD))5.57 (1.00)7.01 (1.13) < 0.001Muscle_quality_diagnosis (%)High muscle quality0 ( 0.0)1544 (100.0) < 0.001Low muscle quality329 (100.0)0 ( 0.0)Muscular_strength (mean (SD))19.24 (6.49)31.35 (14.57) < 0.001Muscular_strength_diagnosis (%)High muscular strength57 ( 17.3)1544 (100.0) < 0.001Low muscular strength272 ( 82.7)0 ( 0.0)ASM (mean (SD))13.27 (3.56)17.87 (3.94) < 0.001Height (mean (SD))153.08 (8.72)158.90 (8.88) < 0.001Weight (mean (SD))43.92 (5.40)61.88 (9.53) < 0.001BMI (%)Underweight136 ( 41.3)0 ( 0.0) < 0.001Normal weight192 ( 58.4)751 ( 48.6)Overweight1 ( 0.3)609 ( 39.4)Obese0 ( 0.0)184 ( 11.9)Waist_circumference (mean (SD))73.16 (10.82)87.23 (12.58) < 0.001ABSI A body shape index, SD standard deviation, GS grip strength, Sec Seconds, BMI body mass index. Baseline characteristic analysis of the participants ABSI A body shape index, SD standard deviation, GS grip strength, Sec Seconds, BMI body mass index. Table 2The ABSI quartile BMI classification tableABSIABSI_1BMISarcopenia4.638314Q4Normal weightNon_sarcopenia4.557812Q4Normal weightNon_sarcopenia4.254811Q4Normal weightNon_sarcopenia7.399006Q4UnderweightSarcopenia6.070689Q4UnderweightSarcopenia4.235808Q4Normal weightNon_sarcopenia4.522269Q4Normal weightNon_sarcopenia4.473606Q4Normal weightNon_sarcopenia4.257242Q4Normal weightNon_sarcopenia5.235611Q4UnderweightSarcopenia4.473394Q4Normal weightNon_sarcopenia6.285027Q4UnderweightSarcopenia4.242901Q4Normal weightNon_sarcopenia5.683479Q4UnderweightSarcopenia4.41169Q4Normal weightNon_sarcopenia4.285241Q4Normal weightNon_sarcopenia5.497933Q4UnderweightSarcopenia4.635501Q4Normal weightSarcopenia4.283908Q4Normal weightNon_sarcopenia4.178743Q4Normal weightNon_sarcopenia4.751603Q4Normal weightNon_sarcopenia5.102532Q4UnderweightSarcopenia4.186851Q4Normal weightNon_sarcopenia4.235321Q4Normal weightNon_sarcopenia4.291753Q4Normal weightNon_sarcopenia4.245307Q4Normal weightNon_sarcopenia5.70972Q4UnderweightSarcopenia4.561631Q4Normal weightNon_sarcopenia5.900749Q4UnderweightSarcopenia4.226834Q4Normal weightNon_sarcopenia4.273165Q4Normal weightNon_sarcopenia4.420706Q4Normal weightNon_sarcopenia4.395983Q4Normal weightNon_sarcopenia5.926585Q4UnderweightSarcopenia4.311979Q4Normal weightNon_sarcopenia4.398941Q4Normal weightNon_sarcopenia5.267373Q4UnderweightSarcopenia6.167406Q4UnderweightSarcopenia6.403124Q4UnderweightSarcopenia4.26876Q4Normal weightSarcopenia4.288537Q4Normal weightNon_sarcopenia4.183899Q4Normal weightNon_sarcopenia4.323051Q4Normal weightNon_sarcopenia4.283391Q4Normal weightNon_sarcopenia4.504335Q4Normal weightNon_sarcopenia5.41665Q4UnderweightSarcopenia4.36588Q4Normal weightNon_sarcopenia4.406229Q4Normal weightNon_sarcopenia4.333Q4Normal weightSarcopenia4.473427Q4Normal weightNon_sarcopenia4.322941Q4Normal weightNon_sarcopenia4.279298Q4Normal weightNon_sarcopenia4.203531Q4Normal weightNon_sarcopenia4.378591Q4Normal weightNon_sarcopenia4.331641Q4Normal weightNon_sarcopenia4.866748Q4Normal weightNon_sarcopenia4.183566Q4Normal weightNon_sarcopenia4.5755Q4Normal weightNon_sarcopenia5.604355Q4UnderweightSarcopenia5.501778Q4UnderweightSarcopenia4.256737Q4Normal weightSarcopenia6.377073Q4UnderweightSarcopenia4.671774Q4Normal weightNon_sarcopenia4.191127Q4Normal weightSarcopenia4.506913Q4Normal weightNon_sarcopenia5.597231Q4UnderweightSarcopenia4.632497Q4Normal weightNon_sarcopenia4.346884Q4Normal weightNon_sarcopenia4.501246Q4Normal weightNon_sarcopenia4.549176Q4Normal weightNon_sarcopenia4.270237Q4Normal weightNon_sarcopenia4.379806Q4Normal weightNon_sarcopenia4.230625Q4Normal weightNon_sarcopenia4.542035Q4Normal weightNon_sarcopenia4.865234Q4Normal weightNon_sarcopenia4.584286Q4Normal weightNon_sarcopenia4.31009Q4Normal weightNon_sarcopenia4.228733Q4Normal weightNon_sarcopenia4.441327Q4Normal weightNon_sarcopenia4.336703Q4Normal weightNon_sarcopenia5.210876Q4UnderweightSarcopenia4.363753Q4Normal weightNon_sarcopenia4.452845Q4Normal weightNon_sarcopenia4.269671Q4Normal weightNon_sarcopenia5.004518Q4UnderweightSarcopenia4.525832Q4Normal weightNon_sarcopenia4.249Q4Normal weightNon_sarcopenia4.259266Q4Normal weightNon_sarcopenia4.427249Q4Normal weightNon_sarcopenia4.458493Q4Normal weightNon_sarcopenia4.475261Q4Normal weightNon_sarcopenia4.187679Q4Normal weightNon_sarcopenia4.231281Q4Normal weightNon_sarcopenia4.442931Q4Normal weightNon_sarcopenia4.37404Q4Normal weightNon_sarcopenia4.832043Q4Normal weightNon_sarcopenia5.657667Q4UnderweightSarcopenia5.795157Q4UnderweightSarcopenia5.840777Q4UnderweightSarcopenia5.75006Q4UnderweightSarcopenia4.639992Q4Normal weightNon_sarcopenia4.402077Q4Normal weightNon_sarcopenia4.412616Q4Normal weightNon_sarcopenia4.388037Q4Normal weightNon_sarcopenia4.923529Q4Normal weightNon_sarcopenia4.692086Q4Normal weightNon_sarcopenia4.24984Q4Normal weightNon_sarcopenia4.321464Q4Normal weightNon_sarcopenia4.454625Q4Normal weightNon_sarcopenia4.576621Q4Normal weightNon_sarcopenia4.616497Q4Normal weightNon_sarcopenia4.181073Q4Normal weightSarcopenia4.317543Q4Normal weightNon_sarcopenia4.230258Q4Normal weightNon_sarcopenia4.600182Q4Normal weightNon_sarcopenia5.190872Q4UnderweightSarcopenia4.253308Q4Normal weightNon_sarcopenia4.314122Q4Normal weightNon_sarcopenia4.196185Q4Normal weightNon_sarcopenia4.306254Q4Normal weightSarcopenia4.264484Q4Normal weightNon_sarcopenia4.330375Q4Normal weightNon_sarcopenia5.69687Q4UnderweightSarcopenia5.337085Q4UnderweightSarcopenia5.721682Q4UnderweightSarcopenia5.031311Q4Normal weightSarcopenia5.204317Q4UnderweightSarcopenia4.417349Q4Normal weightSarcopenia4.570285Q4Normal weightNon_sarcopenia4.496023Q4Normal weightSarcopenia4.196566Q4Normal weightNon_sarcopenia4.347043Q4Normal weightSarcopenia4.362127Q4Normal weightNon_sarcopenia4.270731Q4Normal weightNon_sarcopenia4.466557Q4Normal weightNon_sarcopenia4.863706Q4Normal weightNon_sarcopenia4.306637Q4Normal weightNon_sarcopenia4.18502Q4Normal weightNon_sarcopenia5.236741Q4UnderweightSarcopenia4.290092Q4Normal weightNon_sarcopenia4.231233Q4Normal weightNon_sarcopenia4.308906Q4Normal weightNon_sarcopenia4.242948Q4Normal weightNon_sarcopenia5.347391Q4UnderweightSarcopenia5.971124Q4UnderweightSarcopenia4.401209Q4Normal weightNon_sarcopenia4.258405Q4Normal weightNon_sarcopenia4.357052Q4Normal weightNon_sarcopenia4.375807Q4Normal weightNon_sarcopenia4.439015Q4Normal weightNon_sarcopenia4.218529Q4Normal weightNon_sarcopenia6.519317Q4UnderweightSarcopenia4.390694Q4Normal weightNon_sarcopenia5.847671Q4UnderweightSarcopenia4.529747Q4Normal weightNon_sarcopenia5.296678Q4UnderweightSarcopenia4.465241Q4Normal weightNon_sarcopenia4.409757Q4Normal weightSarcopenia4.745616Q4Normal weightNon_sarcopenia5.742569Q4UnderweightSarcopenia5.656498Q4UnderweightSarcopenia6.615807Q4UnderweightSarcopenia4.181672Q4Normal weightSarcopenia4.342272Q4Normal weightNon_sarcopenia4.397362Q4Normal weightSarcopenia4.23041Q4Normal weightNon_sarcopenia4.573827Q4Normal weightSarcopenia5.895066Q4UnderweightSarcopenia4.379277Q4Normal weightNon_sarcopenia5.264956Q4UnderweightSarcopenia5.475501Q4UnderweightSarcopenia4.364495Q4Normal weightNon_sarcopenia5.648139Q4UnderweightSarcopenia4.220067Q4Normal weightNon_sarcopenia4.493273Q4Normal weightNon_sarcopenia4.241737Q4Normal weightNon_sarcopenia5.636824Q4UnderweightSarcopenia4.630871Q4Normal weightNon_sarcopenia4.372478Q4Normal weightNon_sarcopenia4.182347Q4Normal weightNon_sarcopenia4.446807Q4Normal weightNon_sarcopenia6.182828Q4UnderweightSarcopenia4.64694Q4Normal weightNon_sarcopenia4.223132Q4Normal weightNon_sarcopenia6.096047Q4UnderweightSarcopenia4.277409Q4Normal weightNon_sarcopenia4.323253Q4Normal weightNon_sarcopenia4.684817Q4Normal weightNon_sarcopenia4.223393Q4Normal weightNon_sarcopenia4.179695Q4Normal weightNon_sarcopenia4.1968Q4Normal weightNon_sarcopenia6.783911Q4UnderweightSarcopenia5.220653Q4Normal weightSarcopenia4.625796Q4Normal weightNon_sarcopenia4.194381Q4Normal weightNon_sarcopenia4.307821Q4Normal weightNon_sarcopenia4.29772Q4Normal weightNon_sarcopenia4.564107Q4Normal weightNon_sarcopenia4.232933Q4Normal weightNon_sarcopenia4.20318Q4Normal weightNon_sarcopenia4.788759Q4ObeseNon_sarcopenia4.389952Q4Normal weightSarcopenia5.199168Q4UnderweightSarcopenia5.970384Q4UnderweightSarcopenia6.107819Q4UnderweightSarcopenia4.272127Q4Normal weightNon_sarcopenia4.68764Q4Normal weightNon_sarcopenia4.412089Q4Normal weightNon_sarcopenia4.761971Q4Normal weightSarcopenia4.416439Q4Normal weightNon_sarcopenia4.39129Q4Normal weightNon_sarcopenia4.367658Q4Normal weightNon_sarcopenia4.368056Q4Normal weightNon_sarcopenia6.683729Q4UnderweightSarcopenia4.223324Q4Normal weightNon_sarcopenia4.667663Q4Normal weightNon_sarcopenia4.774734Q4Normal weightNon_sarcopenia4.285324Q4Normal weightNon_sarcopenia4.631325Q4Normal weightNon_sarcopenia4.300815Q4Normal weightNon_sarcopenia5.672634Q4UnderweightSarcopenia5.656476Q4UnderweightSarcopenia4.244497Q4Normal weightNon_sarcopenia4.370203Q4Normal weightNon_sarcopenia4.251233Q4Normal weightNon_sarcopenia4.293205Q4Normal weightNon_sarcopenia4.200136Q4Normal weightSarcopenia4.182046Q4Normal weightNon_sarcopenia4.598027Q4Normal weightNon_sarcopenia4.375631Q4Normal weightNon_sarcopenia4.721021Q4Normal weightNon_sarcopenia4.181445Q4Normal weightNon_sarcopenia5.137674Q4UnderweightSarcopenia4.231365Q4Normal weightNon_sarcopenia4.362938Q4Normal weightNon_sarcopenia4.227252Q4Normal weightNon_sarcopenia5.5068Q4UnderweightSarcopenia4.617238Q4Normal weightNon_sarcopenia4.335104Q4Normal weightNon_sarcopenia4.716545Q4Normal weightNon_sarcopenia4.638178Q4Normal weightNon_sarcopenia4.349356Q4Normal weightNon_sarcopenia4.218318Q4Normal weightNon_sarcopenia4.267266Q4Normal weightNon_sarcopenia4.43579Q4Normal weightNon_sarcopenia5.343155Q4UnderweightSarcopenia4.47179Q4Normal weightSarcopenia4.50083Q4Normal weightNon_sarcopenia4.520369Q4Normal weightNon_sarcopenia4.382544Q4Normal weightNon_sarcopenia6.34471Q4UnderweightSarcopenia5.57698Q4UnderweightSarcopenia4.42441Q4Normal weightNon_sarcopenia5.168883Q4UnderweightSarcopenia4.493642Q4Normal weightNon_sarcopenia4.265202Q4Normal weightNon_sarcopenia4.396829Q4Normal weightNon_sarcopenia5.664721Q4UnderweightSarcopenia4.386757Q4Normal weightNon_sarcopenia6.128004Q4UnderweightSarcopenia4.609099Q4Normal weightNon_sarcopenia5.799416Q4UnderweightSarcopenia4.486169Q4Normal weightNon_sarcopenia4.516208Q4Normal weightNon_sarcopenia4.19134Q4Normal weightNon_sarcopenia4.204672Q4Normal weightSarcopenia5.877831Q4UnderweightSarcopenia4.219256Q4OverweightNon_sarcopenia5.534735Q4UnderweightSarcopenia4.658791Q4UnderweightSarcopenia5.492878Q4UnderweightSarcopenia4.285929Q4Normal weightNon_sarcopenia4.442532Q4Normal weightNon_sarcopenia4.339239Q4Normal weightNon_sarcopenia4.31664Q4Normal weightNon_sarcopenia4.673863Q4Normal weightNon_sarcopenia4.511361Q4Normal weightNon_sarcopenia4.59878Q4Normal weightNon_sarcopenia5.160385Q4UnderweightSarcopenia5.579677Q4UnderweightSarcopenia4.362242Q4Normal weightNon_sarcopenia4.508065Q4Normal weightNon_sarcopenia4.32228Q4Normal weightNon_sarcopenia5.890576Q4UnderweightSarcopenia4.179491Q4Normal weightNon_sarcopenia4.355058Q4Normal weightNon_sarcopenia4.310964Q4Normal weightNon_sarcopenia4.651577Q4Normal weightNon_sarcopenia4.397487Q4Normal weightNon_sarcopenia5.155519Q4UnderweightSarcopenia4.322021Q4Normal weightNon_sarcopenia4.763293Q4Normal weightSarcopenia4.382149Q4Normal weightNon_sarcopenia5.044086Q4OverweightNon_sarcopenia4.300043Q4Normal weightNon_sarcopenia4.27567Q4Normal weightNon_sarcopenia6.25915Q4UnderweightSarcopenia5.073643Q4UnderweightSarcopenia5.691024Q4UnderweightSarcopenia5.020184Q4UnderweightSarcopenia4.273165Q4Normal weightNon_sarcopenia4.342999Q4Normal weightNon_sarcopenia5.564682Q4UnderweightSarcopenia4.385227Q4Normal weightNon_sarcopenia4.518477Q4Normal weightNon_sarcopenia4.473168Q4Normal weightNon_sarcopenia4.884754Q4UnderweightSarcopenia5.427893Q4UnderweightSarcopenia4.467976Q4Normal weightNon_sarcopenia4.399092Q4Normal weightNon_sarcopenia4.502715Q4Normal weightNon_sarcopenia4.187069Q4Normal weightNon_sarcopenia4.456971Q4Normal weightNon_sarcopenia6.122187Q4UnderweightSarcopenia4.4832Q4Normal weightNon_sarcopenia4.790199Q4Normal weightNon_sarcopenia4.412476Q4Normal weightNon_sarcopenia4.27918Q4Normal weightNon_sarcopenia4.251233Q4Normal weightNon_sarcopenia4.412527Q4Normal weightNon_sarcopenia4.257142Q4Normal weightNon_sarcopenia4.317899Q4Normal weightNon_sarcopenia5.399014Q4UnderweightSarcopenia5.474267Q4UnderweightSarcopenia5.775Q4UnderweightSarcopenia4.337621Q4Normal weightNon_sarcopenia5.796601Q4UnderweightSarcopenia4.262025Q4Normal weightNon_sarcopenia4.210745Q4Normal weightNon_sarcopenia4.282286Q4Normal weightNon_sarcopenia5.176338Q4UnderweightSarcopenia4.344186Q4Normal weightSarcopenia5.372218Q4UnderweightSarcopenia5.535139Q4UnderweightSarcopenia5.844057Q4UnderweightSarcopenia5.360554Q4UnderweightSarcopenia4.952087Q4UnderweightSarcopenia4.610761Q4Normal weightNon_sarcopenia4.386712Q4Normal weightNon_sarcopenia6.049793Q4UnderweightSarcopenia6.146361Q4UnderweightSarcopenia5.778149Q4UnderweightSarcopenia6.025322Q4UnderweightSarcopenia4.970073Q4UnderweightSarcopenia5.570829Q4UnderweightSarcopenia6.079366Q4UnderweightSarcopenia5.862805Q4UnderweightSarcopenia4.276609Q4Normal weightNon_sarcopenia5.264207Q4UnderweightSarcopenia4.383771Q4Normal weightNon_sarcopenia4.563679Q4Normal weightNon_sarcopenia4.295431Q4Normal weightNon_sarcopenia4.297942Q4Normal weightSarcopenia4.817691Q4Normal weightNon_sarcopenia4.406486Q4Normal weightNon_sarcopenia4.392399Q4Normal weightNon_sarcopenia4.281383Q4Normal weightNon_sarcopenia4.202326Q4Normal weightNon_sarcopenia4.278942Q4Normal weightNon_sarcopenia4.71564Q4Normal weightNon_sarcopenia5.386049Q4Normal weightSarcopenia4.221479Q4Normal weightSarcopenia4.241557Q4Normal weightSarcopenia6.09953Q4UnderweightSarcopenia4.377059Q4Normal weightNon_sarcopenia4.437996Q4Normal weightNon_sarcopenia4.176608Q4Normal weightNon_sarcopenia6.172606Q4UnderweightSarcopenia4.274582Q4Normal weightNon_sarcopenia4.697897Q4Normal weightSarcopenia4.29182Q4Normal weightNon_sarcopenia4.462581Q4Normal weightNon_sarcopenia4.670934Q4Normal weightSarcopenia4.636023Q4Normal weightNon_sarcopenia4.26068Q4Normal weightNon_sarcopenia5.439305Q4UnderweightSarcopenia5.867187Q4UnderweightSarcopenia4.284376Q4Normal weightNon_sarcopenia4.481761Q4Normal weightNon_sarcopenia4.412045Q4Normal weightNon_sarcopenia4.311189Q4Normal weightNon_sarcopenia4.325872Q4Normal weightNon_sarcopenia4.536656Q4Normal weightNon_sarcopenia4.376419Q4Normal weightNon_sarcopenia4.189658Q4Normal weightNon_sarcopenia4.608637Q4Normal weightNon_sarcopenia6.437455Q4UnderweightSarcopenia4.342038Q4Normal weightNon_sarcopenia4.370609Q4Normal weightNon_sarcopenia4.205236Q4Normal weightNon_sarcopenia5.980591Q4UnderweightSarcopenia4.319214Q4Normal weightNon_sarcopenia4.311013Q4Normal weightSarcopenia5.64994Q4UnderweightSarcopenia4.987994Q4Normal weightNon_sarcopenia4.193891Q4Normal weightNon_sarcopenia4.515637Q4Normal weightNon_sarcopenia4.25067Q4Normal weightNon_sarcopenia4.347062Q4Normal weightNon_sarcopenia4.383824Q4Normal weightNon_sarcopenia4.202039Q4Normal weightNon_sarcopenia6.008328Q4UnderweightSarcopenia4.821759Q4Normal weightNon_sarcopenia6.305926Q4UnderweightSarcopenia4.387455Q4Normal weightNon_sarcopenia4.243806Q4Normal weightNon_sarcopenia4.242409Q4Normal weightNon_sarcopenia4.327901Q4Normal weightNon_sarcopenia4.255865Q4Normal weightNon_sarcopenia4.240103Q4Normal weightNon_sarcopenia5.35718Q4UnderweightSarcopenia5.394027Q4UnderweightSarcopenia4.40895Q4Normal weightSarcopenia4.232658Q4Normal weightNon_sarcopenia5.544959Q4UnderweightSarcopenia4.461295Q4Normal weightNon_sarcopenia4.224207Q4Normal weightNon_sarcopenia5.510093Q4UnderweightSarcopenia4.27705Q4Normal weightNon_sarcopenia4.785404Q4Normal weightNon_sarcopenia4.181365Q4Normal weightNon_sarcopenia5.583053Q4UnderweightSarcopenia5.28762Q4UnderweightSarcopenia6.975176Q4UnderweightSarcopenia4.273495Q4Normal weightNon_sarcopenia6.05842Q4UnderweightSarcopenia5.915357Q4UnderweightSarcopenia6.160379Q4UnderweightSarcopenia4.374814Q4Normal weightNon_sarcopenia4.403976Q4Normal weightNon_sarcopenia5.648034Q4UnderweightSarcopenia5.821023Q4UnderweightSarcopenia5.573704Q4UnderweightSarcopenia5.778015Q4UnderweightSarcopenia6.088959Q4UnderweightSarcopenia4.24565Q4Normal weightNon_sarcopenia4.209206Q4Normal weightNon_sarcopenia5.797126Q4UnderweightSarcopenia4.80996Q4Normal weightSarcopenia4.324875Q4Normal weightNon_sarcopenia4.260773Q4Normal weightNon_sarcopenia4.212502Q4Normal weightNon_sarcopenia6.064306Q4UnderweightSarcopenia4.229888Q4Normal weightNon_sarcopenia6.166475Q4UnderweightSarcopenia4.27919Q4Normal weightNon_sarcopenia4.211965Q4Normal weightNon_sarcopenia6.58795Q4UnderweightSarcopenia4.200208Q4Normal weightNon_sarcopenia4.495923Q4Normal weightNon_sarcopenia4.29405Q4Normal weightNon_sarcopenia4.325623Q4Normal weightNon_sarcopenia5.573089Q4UnderweightSarcopenia4.323512Q4Normal weightSarcopenia5.382588Q4UnderweightSarcopenia5.370839Q4UnderweightSarcopenia4.367726Q4Normal weightNon_sarcopenia6.641574Q4UnderweightSarcopenia4.623445Q4Normal weightSarcopenia4.282313Q4Normal weightSarcopenia5.916667Q4UnderweightSarcopenia4.256516Q4Normal weightNon_sarcopenia4.556854Q4Normal weightSarcopenia4.193878Q4Normal weightNon_sarcopenia4.23593Q4Normal weightNon_sarcopenia4.211456Q4Normal weightNon_sarcopenia5.556447Q4UnderweightSarcopenia5.823479Q4UnderweightSarcopenia4.348902Q4Normal weightNon_sarcopenia The ABSI quartile BMI classification table Table 3Association between ABSI and risk of sarcopeniaSIIOR95% CIp_valueABSImodel 15.854.73–7.33 < 0.001ABSImodel 25.344.23–6.83 < 0.001ABSImodel 35.224.10–6.74 < 0.001Model 1 was included as the exposure factor ABSI and the outcome sarcopeniaModel 2 incorporates covariates such as gender, age and marital status on the basis of Model 1Model 3was further adjusted based on Model 2, including factors such as history of falls, history of hip fractures, any issues affecting balance, smoking, engagement in agricultural work for more than 10 years, physical exercise, healthy lifestyle score, depression, presence of chronic diseases, sleep duration, alcohol consumption, self-rated physical health, life satisfaction, and type of health insurance enrolled in ABSI A body shape index, OR odds ratios, CI confidence intervals Association between ABSI and risk of sarcopenia Model 1 was included as the exposure factor ABSI and the outcome sarcopenia Model 2 incorporates covariates such as gender, age and marital status on the basis of Model 1 Model 3was further adjusted based on Model 2, including factors such as history of falls, history of hip fractures, any issues affecting balance, smoking, engagement in agricultural work for more than 10 years, physical exercise, healthy lifestyle score, depression, presence of chronic diseases, sleep duration, alcohol consumption, self-rated physical health, life satisfaction, and type of health insurance enrolled in ABSI A body shape index, OR odds ratios, CI confidence intervals In addition, hip fracture (Yes), smoking (Yes), depression (Yes), self-rated health (very poor), and life satisfaction (very good) (OR > 1, P < 0.05) were identified as factors associated with sarcopenia. Physical exercise (Yes) and age categories of 45–60 years and 61–75 years (OR < 1, P < 0.05) were identified as protective factors against sarcopenia. Notably, ABSI exhibited the highest OR value at 5.22, indicating that for each 1-unit increase in ABSI, the odds of sarcopenia occurrence were 5.22 times higher, with the association reaching statistical significance. These results highlight the pivotal role of ABSI in the increased likelihood of sarcopenia (Fig. 2).Fig. 2Subgroup analysis of the risk association between ABSI and sarcopenia. From left to right, the figure displays the exposure factors and covariates, corresponding p values, odds ratios (ORs), and 95% confidence intervals (CIs). Narrower CIs correspond to higher statistical precision. An OR < 1 denotes a protective factor, whereas an OR > 1 denotes a risk factor. As illustrated, ABSI exerted a significant influence on sarcopenia and was identified as a risk factor (P < 0.001, OR 5.22, 95%CI 4.10–6.74) Subgroup analysis of the risk association between ABSI and sarcopenia. From left to right, the figure displays the exposure factors and covariates, corresponding p values, odds ratios (ORs), and 95% confidence intervals (CIs). Narrower CIs correspond to higher statistical precision. An OR < 1 denotes a protective factor, whereas an OR > 1 denotes a risk factor. As illustrated, ABSI exerted a significant influence on sarcopenia and was identified as a risk factor (P < 0.001, OR 5.22, 95%CI 4.10–6.74) Strong correlation between ABSI and sarcopenia The area under the curve (AUC) value of the ROC curve for Model 1 was 0.760, indicating good predictive capability (Fig. 3). The AUC values for BMI and WC were 0.856 and 0.875, respectively, both exceeding 0.7, thereby indicating strong predictive performance (Figs. 4, 5). The AUC value for ABSI was 0.871 in the ROC curve, suggesting high accuracy in predicting sarcopenia (Fig. 6). However, the ROC analysis revealed that the AUC value for the training set was 0.871, whereas the value for cross-validation was 0.5, indicating model overfitting. Consequently, regularized logistic regression was applied to optimize the model, resulting in an AUC value of 0.869 after regularization (Fig. 7). Construction of the KNN model identified ABSI as the most influential factor in relation to sarcopenia, followed by age (Fig. 8). Furthermore, a nonlinear association between ABSI and sarcopenia was observed. Specifically, ABSI acted as a protective factor (OR < 1, P < 0.05) when ABSI ≤ 4.7, and as a risk factor (OR > 1, P < 0.05) when ABSI > 4.7 (Fig. 9). In this context, OR values < 1 indicate a protective effect, whereas OR values > 1 indicate an increased risk.Fig. 3ROC curve for model 1Fig. 4ROC curve for BMIFig. 5ROC curve for WCFig. 6ROC curves for ABSI and covariates predicting sarcopenia risk. The x-axis represents the false positive rate (1-specificity), and the y-axis represents the true positive rate (sensitivity). AUC denotes the area under the ROC curveFig. 7Cross-validation ROC curveFig. 8KNN analysis depicting the relative importance of variables in predicting sarcopenia. The horizontal axis represents the variable importance score, with higher values indicating greater predictive value for classification accuracy. ABSI demonstrated the highest predictive importance, surpassing that of age and physical exerciseFig. 9RCS curve illustrating the nonlinear relationship between ABSI and sarcopenia. (1) When ABSI ≤ 4.7, it functioned as a protective factor for sarcopenia (OR < 1, P < 0.05). (2) When ABSI > 4.7, it acted as a risk factor (OR > 1, P < 0.05) ROC curve for model 1 ROC curve for BMI ROC curve for WC ROC curves for ABSI and covariates predicting sarcopenia risk. The x-axis represents the false positive rate (1-specificity), and the y-axis represents the true positive rate (sensitivity). AUC denotes the area under the ROC curve Cross-validation ROC curve KNN analysis depicting the relative importance of variables in predicting sarcopenia. The horizontal axis represents the variable importance score, with higher values indicating greater predictive value for classification accuracy. ABSI demonstrated the highest predictive importance, surpassing that of age and physical exercise RCS curve illustrating the nonlinear relationship between ABSI and sarcopenia. (1) When ABSI ≤ 4.7, it functioned as a protective factor for sarcopenia (OR < 1, P < 0.05). (2) When ABSI > 4.7, it acted as a risk factor (OR > 1, P < 0.05) Discussion Studies utilizing the CHARLS database have reported a relatively high prevalence of sarcopenia among older adults in China, with rural residents being more likely to develop sarcopenia than their urban counterparts [40]. Previous research has indicated that the coexistence of elevated ABSI values and sarcopenia is associated with a markedly increased risk of mortality [41]. For instance, individuals presenting with both low GS and high ABSI have demonstrated higher mortality rates [42]. ABSI has been demonstrated to independently identify elevated cardiovascular disease (CVD) risk associated with skeletal muscle loss, irrespective of BMI [43]. The central obesity reflected by ABSI may synergistically accelerate muscle wasting through the combined effects of aging, physical inactivity, and the release of pro-inflammatory cytokines [44, 45]. By compensating for the limitations of BMI, ABSI enables more effective risk stratification and facilitates the personalization of risk screening [46]. This study found a significant association between ABSI and sarcopenia risk in the Chinese middle-aged and elderly population, with ABSI > 4.7 identified as an independent risk factor. ROC curve analysis further validated the predictive efficacy of ABSI (AUC = 0.871), demonstrating its superiority over traditional indicators, such as BMI and WC. These findings suggest that ABSI can serve as a simple and cost-effective early screening tool, particularly valuable in resource-limited settings, to identify high-risk individuals and facilitate timely interventions for delaying sarcopenia progression. Based on the ABSI calculation formula established by Chinese scholar Wang Hongli et al. in 2020 for assessing physical characteristics of the Chinese population [47], this study validated its clinical value in sarcopenia assessment among middle-aged and elderly populations. ABSI has been shown to offer notable advantages over traditional indicators, such as BMI and WC, in the identification of sarcopenia. These advantages are primarily attributed to its unique formula, which comprehensively integrates three essential parameters: weight, height, and WC [48]. The innovative calculation incorporates dual corrections through: (1) the BMI2/3 term, which addresses the overestimation of muscle mass in obesity, and (2) the height1/2 component, which mitigates height-related bias inherent in isolated WC measurements [18]. These features render ABSI particularly valuable for the early detection of sarcopenic obesity associated with visceral adiposity [49] and for the evaluation of individuals with a normal BMI but central obesity [10, 50]. The ABSI cutoff identified in this study is consistent with the findings from Qiao et al. [12] and Keun et al. [51] supporting its cross-cultural applicability. Furthermore, this threshold provides a clear screening criterion for clinical practice. Although certain limitations may arise in extremely cachectic populations, the mathematical refinement of ABSI constitutes a substantial advancement over conventional anthropometric measures, enabling clinicians to achieve greater precision in muscle mass assessment and metabolic risk stratification [52–54]. The study results indicate that the mean ABSI in patients with sarcopenia (4.59) was significantly greater than that in the non-sarcopenia group (3.71). This difference remained stable after controlling for multidimensional confounding factors, including demographics, lifestyle, and clinical characteristics (adjusted OR 5.22, 95% CI 4.10–6.74 in Model 3). This finding not only confirms ABSI’s effectiveness as a strong indicator of sarcopenia risk in the Chinese middle-aged and elderly population, but also underscores its value as an independent predictor. A systematic approach to covariate selection was employed in this study, based on established determinants of sarcopenia risk, including sex, age, history of falls, and clinically validated confounders, such as aging, adverse lifestyle factors, depression, and comorbidities [3, 21, 55]. Using multivariable regression models with sequential covariate adjustments (Model 1 to Model 3), a nonlinear association between ABSI and sarcopenia risk was identified: ABSI was associated with a protective effect at lower ranges but became a significant risk factor (P < 0.05) when exceeding the critical threshold of 4.7 (Model 3, fully adjusted). Cross-sectional analysis indicated that sarcopenia differed significantly with respect to age, physical exercise, sleep duration, and marital status. A longitudinal study reported a relatively high prevalence and mortality of sarcopenia among older adults in China [56]. These findings were consistent with these results, as more cases were observed among individuals aged over 75 years. Previous research has shown that exercise can delay the progression and reduce the rate of sarcopenia [57]. However, stratified analysis in this study revealed that physical exercise acted as a protective factor against sarcopenia. Jiang et al. used nationally representative data from CHARLS to study 7703 individuals aged over 45 years and found that sarcopenic obesity (or possible sarcopenic obesity) was positively associated with the occurrence of CVD [58]. Zhong et al. used CHARLS (2015) to study 14,258 individuals aged 40 years and above and found that depression contributed to the development of sarcopenia. Timely recognition and management of depression may represent an important strategy for preventing sarcopenia [59]. Chen et al. used CHARLS to examine 1819 participants aged over 60 years without sarcopenia and determined that BMI played a mediating role between sarcopenia and the TyG index in the Chinese older adult population [60]. Du et al. analyzed data from 2391 participants aged over 60 years in CHARLS (2015) and found that possible sarcopenia was associated with an elevated risk of cognitive decline in the Chinese population [61]. ABSI has been found to independently predict FFMI in females and serves as a significant predictor of sarcopenic obesity [62]. An analysis based on data from U.S. and Korean adults demonstrated a rapid increase in the odds of sarcopenia with higher log-transformed A-body size index cut-points [63]. In this study, the RCS curve similarly indicated that ABSI became a risk factor for sarcopenia when exceeding a threshold of 4.7. Another investigation reported that FFMI was significantly higher in both males and females with lower ABSI compared to those in the higher ABSI group, suggesting its potential utility in assessing sarcopenia risk among overweight or obese individuals [10]. Previous studies have reported a negative correlation between the ABSI and the FFMI, identifying ABSI as an independent predictor of muscle depletion syndrome [64]. This study systematically examined the role of ABSI as an independent risk factor through stepwise adjustment across three statistical models. Using ROC curve analysis and evaluation via the KNN algorithm, its predictive capacity and relative importance among covariates were further assessed. This research addresses a key gap in the existing literature regarding the independent association between ABSI and muscle depletion syndrome, particularly with respect to methodological rigor. Methodologically, the study adopted the internationally recognized AWGS 2019 criteria to diagnose sarcopenia and incorporated a nationally representative CHARLS sample (representing Chinese adults aged 45 and above, with a mean age of 62.3 years), significantly enhancing the reliability and generalizability of the findings. In practical terms, the ABSI cutoff value (4.7) established in this study demonstrated excellent predictive performance (AUC = 0.871), showing clear advantages over traditional screening methods. Since ABSI requires only basic anthropometric measurements, its cost-effective and simple operation makes it particularly suitable for resource-limited primary healthcare settings, holding particular value in rural applications. This effectively addresses the gap in early management tools for sarcopenia across different healthcare systems. The comprehensive analytical framework applied herein not only confirms the clinical relevance of ABSI but also offers novel insights and practical tools for the early diagnosis and targeted intervention of muscle-related disorders. However, this study has several limitations. First, the cross-sectional design cannot establish causality between ABSI and sarcopenia. Second, the exclusion of numerous individuals with incomplete data during sample screening may affect the representativeness of the results, particularly highlighting the under-representation of rural elderly populations. Third, the applicability of ABSI in individuals with extreme body types remains unclear. Fourth, although multiple covariates were adjusted for in the analysis, potential confounding factors such as dietary nutrition were not included, which could influence the strength of the association analysis. Fifth, the BIA method used to diagnose sarcopenia may yield biased muscle mass measurements in obese populations, necessitating further calibration with imaging methods. Finally, the machine learning models employed exhibited overfitting, indicating that algorithm optimization remains a key challenge for future research. Future studies should: conduct multicenter longitudinal research to clarify causal relationships; expand sample sizes to include more population subgroups for validating the generalizability of ABSI; and develop screening tools combining ABSI with other simple indicators. These efforts will help establish the clinical utility of ABSI for early sarcopenia screening and prevention, facilitating its inclusion in international sarcopenia diagnostic consensus guidelines. Conclusion ABSI was found to be significantly associated with sarcopenia and identified as a risk factor, thereby providing an evidential basis for both the understanding and prevention of the condition. It is anticipated that ABSI could be applied for the early identification of populations at high risk for sarcopenia, enabling the timely implementation of preventive and therapeutic measures aimed at improving disease outcomes. Supplementary Information Additional file1 (XLS 23 kb) Table S1. Specific information on covariates. The range for chronic disease scores was 0–14. Depression status was assessed in CHARLS using the 10-item Center for Epidemiological Studies–Depression Scale (CES-D10). This scale contains 10 items, each with four response options, scored from 0 to 3, estimating depressive symptoms and behaviors over the preceding week. A total score ≥ 12 (range: 0–30) was considered indicative of depression. A “healthy style” was defined as meeting the following criteria: non-smoker, non-drinker, participation in physical exercise, sleep duration > 6 h, and BMI within 18.5–24 kg/m2. Additional file1 (XLS 23 kb) Table S1. Specific information on covariates. The range for chronic disease scores was 0–14. Depression status was assessed in CHARLS using the 10-item Center for Epidemiological Studies–Depression Scale (CES-D10). This scale contains 10 items, each with four response options, scored from 0 to 3, estimating depressive symptoms and behaviors over the preceding week. A total score ≥ 12 (range: 0–30) was considered indicative of depression. A “healthy style” was defined as meeting the following criteria: non-smoker, non-drinker, participation in physical exercise, sleep duration > 6 h, and BMI within 18.5–24 kg/m2.